Atezolizumab with bevacizumab recommended for advanced or unresectable hepatocellular carcinoma
Results of an indirect comparison suggest that atezolizumab plus bevacizumab is more effective than lenvatinib.
Published
Join OnMedica and benefit from:
- Bitesize CPD and easy to digest content, free for UK-based GPs and specialist doctors
- High-quality, evidence-based content developed by expert editors and clinicians
- Articles, quizzes, videos, visual summaries and more
- Regulatory alerts and round-up of medical journals
- New content added daily, so you know you’re always up to date
